Aquestive Therapeutics Announces Chief Legal Officer Transition and New Appointment
AQST sits 85% above its 52-week low of $2.12.
Summary
Aquestive Therapeutics announced a change in its Chief Legal Officer and Chief Compliance Officer roles, with Lori J. Braender stepping down and Thomas A. Zalewski appointed as her successor, accompanied by a significant equity vesting for the departing officer.
Key Events · Executive and Board Changes · AQST
-
Executive Departure
Lori J. Braender is stepping down as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, but will remain as Corporate Secretary.
-
Significant Equity Vesting
Ms. Braender will receive full and immediate vesting of all unvested stock options, RSUs, SARs, and other equity awards on May 7, 2026, as part of her separation agreement.
-
New Executive Appointment
Thomas A. Zalewski has been appointed as the new Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, bringing extensive experience in life sciences law.
-
Inducement Equity Grant
Mr. Zalewski will receive an inducement grant of 100,000 Restricted Stock Units and 75,000 non-qualified common stock options, vesting over three years.
Analysis · AQST · Life Sciences
Aquestive Therapeutics is undergoing a significant leadership transition with the departure of its Chief Legal Officer and Chief Compliance Officer, Lori J. Braender, from her executive roles. The immediate vesting of all her unvested equity awards as part of her separation package represents a notable compensation event for the company. The appointment of Thomas A. Zalewski as the new Chief Legal Officer and Chief Compliance Officer provides continuity in a critical function, especially as the company navigates recent FDA approval delays and increased net losses.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AQST was trading at $3.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $495.5M. The 52-week trading range was $2.12 to $7.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.